Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Long-term extension study of upadacitinib in ulcerative colitis
2023-505699-31-00Phase 3Authorised
- Sponsor
- AbbVie Inc.
- Start
- Jan 2017
- Modality
- Small Molecules
- Countries
- 44
01
Overview
Phase 3, open-label, single-arm trial of upadacitinib in autoimmune colitis, sponsored by AbbVie Inc. Primary endpoint: Incidence of adverse events. Planned start Jan 2017; status: authorised.
02
Drugs
upadacitinib
03
Conditions
autoimmune colitis
Beyond the preview
Go deeper on 2023-505699-31-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2023-505699-31-00.